Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1)
Alberto Bresciani(University of Bergamo), Larry C. Park(CHDI Foundation), Daniel O. Cicero(Universidad de Buenos Aires), Ignacio Muñoz-Sanjuán(CHDI Foundation), Mariana Gallo(University of Parma), Mauro Cerretani(IRBM Science Park), Leticia Toledo‐Sherman(CHDI Foundation), Raffaele Ingenito, Celia Dominguez(CHDI Foundation), Elisabetta Bianchi(IRBM Science Park), Alessia Santoprete(IRBM Science Park), Licia Tomei(IRBM Science Park), Sergio Altamura(IRBM Science Park), Paola Fezzardi(IRBM Science Park), Robert E. Pacifici(CHDI Foundation), Steven J. Harper(Northwestern University), Antonino Missineo(IRBM Science Park)
Cited by 45
Related Papers
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848
Characterization of Neurophysiological and Behavioral Changes, MRI Brain Volumetry and 1H MRS in zQ175 Knock-In Mouse Model of Huntington's Disease
|PLoS ONE|2012|324
A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope
|Proceedings of the National Academy of Sciences|2005|156
Design, Synthesis, and Biological Evaluation of Potent and Selective Class IIa Histone Deacetylase (HDAC) Inhibitors as a Potential Therapy for Huntington’s Disease
|Journal of Medicinal Chemistry|2013|149
Adipogenesis of skeletal muscle fibro/adipogenic progenitors is affected by the WNT5a/GSK3/β-catenin axis
|Cell Death and Differentiation|2020|149